More than 8 million Americans used psilocybin last year
A 2024 federal survey analyzed by the University of Illinois Urbana-Champaign found over 8 million Americans—nearly 3% of the population—used psilocybin in the past year, with users more likely to be younger, white, male, and high-income. Researchers warn of rising polysubstance use, including combining psilocybin with other drugs like ketamine, raising concerns about unregulated consumption and potential health risks outside clinical settings.
A new analysis of federal data reveals that more than 8 million Americans—around 3% of the population—used psilocybin in the past year, far exceeding expectations tied to clinical trials and legal reforms. The study, led by Professor Andrew Yockey and Rachel Hoopsick at the University of Illinois Urbana-Champaign, drew from a 2024 federal survey of 58,000 people aged 12 and older. The findings highlight a demographic skew: users were predominantly younger, white, male, and higher-income, with wealth likely influencing access to legal, supervised therapy sessions costing up to $6,500. Users frequently combined psilocybin with other substances, including alcohol, marijuana, cocaine, ecstasy, LSD, and ketamine—a pattern researchers call polysubstance use. This mixing raises alarms, as interactions between drugs like psilocybin and ketamine remain unstudied, increasing risks of poisoning or accidental death. The survey also noted a stark contrast: heroin users were far less likely to report psilocybin use, suggesting different motivations behind drug choices. Almost all psilocybin consumption occurs outside clinical settings, with no oversight on dosage or product potency. Mushrooms sourced informally carry no labeling, leaving users unaware of active compound levels. The study underscores a growing gap between regulated medical use and unmonitored recreational consumption, particularly as access to psychedelics expands. Researchers emphasize the need for targeted harm-reduction strategies, noting that different drugs attract users seeking distinct experiences. For example, heroin often addresses severe physical or emotional pain, while psilocybin may be pursued for psychedelic effects. The data suggests tailored interventions could better address the risks associated with specific drug combinations and user demographics. The findings challenge the narrative that psilocybin use is limited to controlled clinical environments, revealing a broader, unregulated trend. With public interest in psychedelics rising and legal barriers easing in some states, the study calls for further research into the long-term health impacts of unsupervised use.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.